Chemistry:SRT-1460
From HandWiki
Short description: Chemical compound
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C26H29N5O4S |
Molar mass | 507.61 g·mol−1 |
3D model (JSmol) | |
|
SRT-1460 is a drug in development by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in animal studies to the known SIRT1 activator resveratrol, but is closer in potency to SRT-1720. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function.[1] However, the claim that SRT1460 is a SIRT1 activator has been questioned[2] and further defended.[3]
See also
References
- ↑ "Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes". Nature 450 (7170): 712–6. November 2007. doi:10.1038/nature06261. PMID 18046409. Bibcode: 2007Natur.450..712M.
- ↑ "SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1". The Journal of Biological Chemistry 285 (11): 8340–51. March 2010. doi:10.1074/jbc.M109.088682. PMID 20061378.
- ↑ "SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator". The Journal of Biological Chemistry 285 (43): 32695–703. October 2010. doi:10.1074/jbc.M110.133892. PMID 20702418.
Original source: https://en.wikipedia.org/wiki/SRT-1460.
Read more |